1. Dexycu is applied as a single, post-surgery injection.
2. The drug uses Icon Bioscience’s extended-release drug-dispensing technology to inject dexamethasone into the eye’s posterior chamber.
3. Typical treatment for inflammation after cataract surgery involves self-administering medicated eye drops several times daily for several weeks.
4. More than 4 million cataract surgeries are performed annually in the U.S., on a largely elderly population.
5. “As Icon steps across the threshold from R&D to an approved product, we look forward to announcing our plans to bring Dexycu into the marketplace,” said Icon Bioscience President and CEO David Tierney, MD.
More articles on supply chain:
Medical software company raises $3.2M for value-based IT system – 5 highlights
Terumo Corp. to make major investment in medical implants factory — 5 notes
McKesson reports $53.6B in Q3 revenue — 7 insights
